A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
A Phase 2b/3, randomized, double-blind, multicenter, multinational study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and mPDAC. The first-line chemotherapies will either be nab-paclitaxel plus gemcitabine or FOLFIRINOX (or mFOLFIRINOX). The double-blind period is followed by an optional open-label extension period.
Initial enrollment will be in Phase 2b. If all eligibility criteria are met, participants will be randomized in a 1:1:1 allocation to study intervention (one of the two doses of ponsegromab, or placebo) plus first-line systemic chemotherapy. Participants must have completed their first-line pre-randomization systemic chemotherapy (1 x 28-day cycle of nab-paclitaxel and gemcitabine or 2 x 14-days cycles of FOLFIRINOX) prior to the start of receiving their first dose (Day 1) of study intervention (ponsegromab or placebo). Day 1 study intervention must be taken on the same day participants start their next cycle of nab-paclitaxel and gemcitabine chemotherapy or FOLFIRINOX chemotherapy and prior to receiving chemotherapy. All chemotherapy dosing is to be determined by the participant's health care provider in accordance with local guidelines. Study intervention will be administered Q4W SC.
Following enrollment completion of Phase 2b, Phase 3 enrollment will begin, and eligible participants will be randomized in a 1:1:1 allocation to study intervention (one of the two doses of ponsegromab, or placebo). Participants must have completed their first-line pre-randomization systemic chemotherapy (1 x 28-day cycle of nab-paclitaxel and gemcitabine or 2 x 14-day cycles of FOLFIRINOX) prior to the start of receiving their first dose (Day 1) of study intervention (ponsegromab or placebo). Day 1 study intervention must be taken on the same day participants start their next cycle of nab-paclitaxel and gemcitabine chemotherapy or FOLFIRINOX chemotherapy and prior to receiving chemotherapy. All chemotherapy dosing is to be determined by the participant's health care provider in accordance with local guidelines. Study intervention will be administered Q4W SC.
Once all Phase 2b participants have completed Week 12 procedures, an analysis of Phase 2b will be performed, from which one of the 2 ponsegromab doses will be selected. After the Phase 3 ponsegromab dose has been selected, continuing Phase 2b participants will:
After the ponsegromab dose has been selected, continuing Phase 3 participants will:
During the Phase 3 portion of the study, there will be an optional sub-study for primary caregivers of participants with cachexia and mPDAC to evaluate the effectiveness of ponsegromab in improving the quality of life and well-being of the primary caregivers.
Study intervention (ponsegromab selected dose or placebo) will continue regardless of chemotherapy treatment until permanent discontinuation of study intervention, withdrawal of consent, death, or the end of the Phase 3 double-blind portion of the study has been reached when the approximate number of overall survival events have been accrued for the Phase 3 analysis of overall survival.
Participants will have tumor assessments performed approximately every 6 to 8 weeks during the double-blind period by blinded, independent, central reader radiologists.
When the number of overall survival events has been accrued to terminate the Phase 3 double-blind portion of the study, active participants can continue in the optional open-label extension where they will receive ponsegromab for up to 12 months.
Key inclusion Criteria:
Key Exclusion Criteria:
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Bryant, Arkansas 72022, United States
Conway, Arkansas 72034, United States
North Little Rock, Arkansas 72117, United States
Pine Bluff, Arkansas 71603, United States
Irvine, California 92612, United States
La Jolla, California 92037, United States
Los Angeles, California 90048, United States
Los Angeles, California 90095, United States
San Diego, California 92103, United States
Washington D.C., District of Columbia 20007, United States
Washington D.C., District of Columbia 20007, United States
New Lenox, Illinois 60451, United States
O'Fallon, Illinois 62269, United States
Lexington, Kentucky 40536, United States
Lexington, Kentucky 40536, United States
Baltimore, Maryland 21287, United States
Kansas City, Missouri 64132, United States
Morristown, New Jersey 07960, United States
Somerville, New Jersey 08876, United States
Chapel Hill, North Carolina 27514, United States
Hillsborough, North Carolina 27278, United States
Dallas, Texas 75235, United States
Dallas, Texas 75235, United States
Dallas, Texas 75390, United States
Milwaukee, Wisconsin 53226, United States
Toronto, Ontario M5G 2M9, Canada
Greenfield Park, Quebec J4V 2H1, Canada
Beijing, Beijing Municipality 100021, China
Shanghai, Shanghai Municipality 200025, China
Hangzhou, Zhejiang 310015, China
Wenzhou, Zhejiang 325000, China
München, Bavaria 81737, Germany
Dresden, Saxony 01307, Germany
Leipzig, Saxony 04103, Germany
München, 81675, Germany
New Delhi, National Capital Territory of Delhi 110029, India
New Delhi, National Capital Territory of Delhi 110085, India
Ramat Gan, Central District 5265601, Israel
Milan, Milan 20162, Italy
Kita-gun, Kagawa-ken 761-0793, Japan
Nagaizumi-cho, Shizuoka 411-8777, Japan
Chuo-ku, Tokyo 104-0045, Japan
Koto-ku, Tokyo 135-8550, Japan
Wakayama-shi Kimiidera 870-2, Wakayama 641-0012, Japan
San Luis Potosí City, 78200, Mexico
Warsaw, Masovian Voivodeship 02-034, Poland
Olsztyn, Warmian-Masurian Voivodeship 10-228, Poland
Mayagüez, 00680, Puerto Rico
Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea
Seoul, Seoul-teukbyeolsi [seoul] 06591, South Korea